Intestinal Biomarkers Respond to Ozanimod

(MedPage Today) -- Treatment with oral ozanimod (Zeposia) reduced markers of intestinal inflammation among patients with moderately to severely active ulcerative colitis, confirming previously demonstrated clinical benefits.Levels of fecal calprotectin...